To hear about similar clinical trials, please enter your email below
Trial Title:
Myeloma Novel Drug Discovery Ver 1.2
NCT ID:
NCT05968417
Condition:
Multiple Myeloma
Conditions: Official terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
Observational study - sample collection only.
Description:
No intervention - blood and/or bone marrow sample collection only
Arm group label:
Participants with a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
Summary:
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year.
Researchers are committed to improving understanding of myeloma and developing more
effective treatments with fewer side effects in order to improve patient outcomes. In
order to do this, researchers are collecting samples of blood and bone marrow to test the
activity of potential new treatments in the laboratory and to understand what may be the
cause of some treatments not working.
Criteria for eligibility:
Study pop:
Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma
cell disorder
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Participants who have a diagnosis, or suspected diagnosis, of myeloma or related
plasma cell disorder
2. Participants who are undergoing a peripheral blood or bone marrow aspirate sampling
for diagnostic, staging or follow-up purposes, before, whilst or after receiving
anti-myeloma treatment
3. Participants aged 18 years of age or above
4. Participants willing to consent to an additional sample being taken at the time of
their peripheral blood or bone marrow aspirate sampling
Exclusion Criteria:
1. Participants unable to provide consent
2. Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID)
that pose a risk to the use of the sample in the laboratory
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
The Royal Marsden NHS Foundation Trust
Address:
City:
London Borough of Sutton
Zip:
SM25PT
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Chloe Burrows
Email:
chloe.burrows@rmh.nhs.uk
Investigator:
Last name:
Charlotte Pawlyn
Email:
Principal Investigator
Start date:
July 22, 2020
Completion date:
February 28, 2035
Lead sponsor:
Agency:
Institute of Cancer Research, United Kingdom
Agency class:
Other
Collaborator:
Agency:
Royal Marsden NHS Foundation Trust
Agency class:
Other
Source:
Institute of Cancer Research, United Kingdom
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05968417
